Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $152.
September 07, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $152.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Ascendis Pharma. The maintained price target of $152 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100